News
![Lilly-logo](https://pharmaphorum.com/wp-content/uploads/2016/06/Lilly-logo.jpg)
Lilly breaks new ground for BTK class with Jaypirca approval
Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla